Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
Study type:
Clinical Trials
Posting date:
08/06/2024
Last updated:
08/06/2024
Status:
Recruiting
Phase:
Phase 2
Country:
United States; Canada
Eligibility:
Drug:
amlitelimab
Administration:
subcutaneous injection
Sponsor:
Sanofi
Sponsor Link:
Click here
ClinicalTrials.gov link:
Click here
Location:
Multiple locations
Description:
Age 18 years or older; definitive diagnosis of AA of more than 6 months; diagnosis of severe AA, as determined by 50% or greater scalp hair loss, current episode of hair loss < 8 years, and no evidence of hair regrowth within 6 months; willingness in maintaining consistent hair style and hair care
Description:
For more information on this study, visit Clinicaltrials.gov or Sanofistudies.com.